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Fake internet medical information, paraphar-
macies and counterfeit drugs constitute a 
market worth hundreds of billions of dollars 
per year1–3 and pose a serious public health 
risk at the global level.4 Exposure of web visi-
tors to fake and misleading information may 
decrease patients’ compliance to medically 
recommended treatments, promote the use 
of questionable and detrimental practices and 
jeopardise patient outcomes and survival.4–6
The threat posed by fake internet medical 
information may be of particular harm to 
patients where the burden of symptoms from 
the disease or treatment significantly influ-
ence quality of life, mood, daily activities 
and occupational and financial prospects or 
activity and family integrity.7 Across a range 
of cancers, where treatment toxicities, malnu-
trition, cachexia and pain can be signifi-
cant factors the substantial functional and 
emotional needs and the motivation to find a 
solution leave patients with cancer and their 
relatives particularly vulnerable to fake infor-
mation and treatments on the internet.
What are the factors that may result in 
patients being exposed to, and potentially 
influenced by, such on- line harm? Clinical 
areas where there is a lack of a high- quality 
research base make it easier for misinforma-
tion to be seen as fact. In cancer medicine, 
for example, research into pain, malnutri-
tion and cachexia does not attract significant 
funding and is not a popular field for oncol-
ogists, researchers or pharmaceutical compa-
nies. This may be as a result of competition 
with research seen as more cutting edge, 
for example, that using genome sequencing 
or translational molecular medicine or 
advanced radiotherapy techniques. It may 
also be a consequence of more difficult to 
define end points for clinical trials in these 
areas. Despite a slow observed improvement 
in symptom management in these areas 
over time, there remains an unmet need to 
adequately address patients’ nutritional and 
analgesic needs.8–11
Supportive service availability beyond 
that provided by oncologists varies among 
different health systems. However, only a few 
countries have structured supportive pain, 
dietetic, psychooncology and palliative care 
teams. A US survey documented that one- 
third of oncology patients do not receive pain 
medications proportional to their pain inten-
sity levels, and concordantly, a European 
survey indicated that half of the European 
oncology patients believe that their quality 
of life is not considered a priority in their 
overall care by healthcare professionals.8–10 
Consequently, the dissatisfaction of patients 
and their relatives is very high and, inevitably, 
they are prone to visit the internet and social 
media (Instagram, Twitter, Facebook, etc) 
which may be felt as unique sources to find 
solutions to their problems and disabilities. 
Exposure on the web to potentially misleading 
data, fake information and the counterfeit 
drug market is therefore maximised.
Globally use of the internet has grown expo-
nentially over the last 20 years.12 In the real 
world, the internet is a complex open- access 
phenomenon with few controls or regula-
tions regarding factual accuracy or sanctions 
against fraudulent activity. One of the instru-
ments that may be best suited to counteract 
the detrimental effects of misleading web 
information and unrestricted access to poten-
tially harmful medicines is through official 
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web recommendations by medical authorities (official 
medical societies/health policy- maker providers) both 
for healthcare providers and for patients and their family 
members.
Acknowledging that most oncologists are not trained, 
have restricted or no time or they do not have estab-
lished tools to support or protect cancer patients from 
internet hazards, who should really support and ‘e- pro-
tect’ patients with cancer?
It could be argued that recognised ‘approved’ medical 
organisations should provide patients protection by 
imparting recommendations directly via the internet. 
Unfortunately, this is not the case. In 2018, only a minority 
of official medical societies provided updated and struc-
tured recommendations to patients and family members 
on their websites.7 In a web survey of 370 oncology/anes-
thesiology societies, the scope and content of recommen-
dations for physicians regarding cancer- related pain and 
cachexia were remarkably inconsistent. The proportion 
of societies providing up- to- date on- line evidence- based 
recommendations to physicians for cancer cachexia was 
only 2.96% (8 of 270)13 and for cancer pain only 4.7% 
(17 of 370).14 Surprisingly, the web guidelines provision 
for physicians was not found to be dependent on human 
development index, geographical region or oncology 
specialisation.
Surprisingly, the paucity of recommendations was 
evident even among the societies of specialties whose 
core purpose is the management of patients with cancer. 
The plethora of medical societies, organisations and 
health policy- makers that have developed over time offer 
a landscape of flourishing professional activity which does 
not seem to translate into adequate provision of practical 
on- line information for patients and family members.
Have we left our patients …‘alone’ in the WEB? Can, in 
the internet era, medical professionals oversee the overall 
management and the on- line support of cancer patients?
If, for example, we again look at the areas of palliative 
and supportive cancer medicine and the drivers to seek 
out on- line information the numbers are impressive. 
Out of the 18 000 000 new cancer cases diagnosed annu-
ally worldwide,15 pain affects more than half of cancer 
patients, with a prevalence of 55% among patients on 
anticancer treatment, 66.4% among those with advanced 
metastatic or terminal phases of the disease, 39.3% 
following curative treatment and with 38% of all patients 
reporting moderate to severe pain.16 17 Conversely, one- 
third of patients with malignancy will suffer of cancer 
cachexia, with this proportion being notably higher 
among patients affected by solid cancers. Cachexia preva-
lence in advanced cancer might be as high as 60%–80%.18
Nutritional issues in patients with cancer are so 
important that the European Cancer Patient Coalition 
(ECPC) published a Cancer Patient’s Nutritional Bill of 
Rights, which was presented in the European Parliament 
in Brussels in November 2017.19
But, … has the scale of this issue been acknowledged or 
reflected in provision of adequate support?
Strongly motivated, anxious or worried patients and 
their family members may surf the internet or share their 
concerns through social media in an attempt to find 
complementary or alternative treatments, seek for clin-
ical trials as well as to address symptoms and find ways to 
improve their quality of life.20 This is especially when they 
feel that they have been let down by the Health System or 
their physicians’ behaviour.21
Nonetheless, in the absence of web recommendation 
from official medical societies, the potential risk for 
patients and family members to be exposed to harmful 
fake internet information with potentially detrimental 
effects on patients’ outcome and survival,4 is significant. 
The plethora of available web and social media informa-
tion (Twitter, Instagram, Facebook etc), makes it diffi-
cult for individuals to be able to filter ‘true’ from ‘false’ 
information. Of note, the use of different social media 
impacts patients’ communication and information vari-
ably. Traditionally, bloggers publish and exchange long 
texts with the major part of contents being shared not in 
real time. Nowadays, bloggers are switched from blogs to 
the more active microblogs (also known as nanoblogs) 
where instant messaging, direct conversations and the 
use of microposts in various content formats (including 
audio, video, images and text) are immediate and super- 
fasts rendering the risk of uncontrolled e- information 
much higher, with low threshold of critical thinking. 
Microblogging is the new form of building connections 
as users continue to turn to mobile solutions as an imme-
diate source of information. In fact, in 2018, the 52.2% 
of website traffic worldwide was generated by mobile 
devices.22 Real- time sharing, frequent posts, fast- paced 
environment and the possibility to maintain relationships 
make microblogs a microenvironment particularly sensi-
tive to e- trade. Here, the potential customers may share 
time- sensitive information and have a personal interac-
tion with sellers. Actually, we have different microblog 
platforms with contents designed for quick interactions 
of different audiences: Facebook (social network site 
where users share text, live videos and more to connect 
each other), Twitter (that allow quick and practical way 
to share short posts, GIFs (Graphics Interchange Format 
images), article links, videos and more), Pinterest (that 
links to products, articles and useful information for audi-
ences) LinkedIn (social network site with professional 
profile); Instagram (visual form of blogging, allowing 
to share stories and snaps). For those reasons, patients’ 
exposure to misleading medical information in microb-
logs’ environment can be maximal.
In this setting, it is easy to identify and describe the 
economic drivers that result in the development forma-
tion of a vicious cycle of misinformation and fraud. The 
potential for enormous profits trigger the paramedical 
markets to self- perpetuating production of more exten-
sive and persuasive misleading information and avail-
ability of counterfeit drugs or quack cures on the internet. 
The increase in web misinformation is so high that it may 
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Figure 1 Fake medicine on the web and the new 
internet e- data outbreak disease: a vicious cycle of 
harmful self- sustaining and unregulated mechanisms 
driven by paramedicine markets profits. Fake medicine 
data outbreaks represent a new and uncontrolled internet 
disease with detrimental impact on patients’ outcome and 
compliance to recommended treatment.
reach the dimension of harmful internet fake- data out 
breaks (figure 1).
Apart parapharmacy, black- drug market and counter-
feits drug market, another issue that is rapidly arising is 
how manage the web information on official but partic-
ularly expensive drugs, especially when promising treat-
ments are addressed on a very early stage in the absence 
of a confirmatory study.23 Redundant and extensive web 
information on a promising but unconfirmed and costly 
treatment may indeed both expose the patients to futile 
hopes and threaten the health systems economics. How to 
inform the media- industry on ‘new, promising but uncon-
firmed and costly drugs and treatments’ is an emerging 
issue that needs to be regulated in the next future.
In the era of ‘new media, fake e- medicine and counter-
feit drug e- market’, medical societies, having been slow 
to capitalise the role of the internet as a tool to assist and 
inform patients and families, have left the door open for 
development of an unregulated and exclusively profit- 
driven sector.
There are convincing data that improved health e- lit-
eracy for patients with cancer and their families is an 
important instrument in understanding and evaluating 
information provided on the internet.24 Therefore, the 
promotion, via the internet, of specific supportive care 
recommendations by official medical societies working 
in partnership with patient organisations directed both 
to physicians (specialists audience) as well as patients 
and their families (general audience), would likely be of 
significant value in protecting various internet threats. It 
will be important to ensure that development of ‘official’ 
on- line e- recommendations be of a consistently high stan-
dard and kept up to date with developments in the field. 
Of course, e- recommendation production should be 
notably improved at the global level. Recommendations 
for the general audience should not be confounded with 
the recommendations/guidelines for specialists since 
the information needs may be different and the use of 
complex, technical language result in confusion.
The provision of patient- specific on- line information 
may be a novel endeavour for official medical societies 
generally devoted to the specialist education of clinicians 
and researchers. Thus, we propose the development of 
a ‘patient corner’ in each society website. This may not 
require all medical societies to have their own patient- 
centred recommendations. We believe in the value of both 
guidelines produced by societies themselves and/or of 
‘links’ to recommendations on the web sites of other offi-
cial medical organisations. To achieve the maximum global 
reach we believe that this form of patient specific guidance 
should be provided, in the local language of the target 
audience. In case of links to international recommenda-
tion, usually written in English, the role of national medical 
societies may be to provide a summary or full translation of 
such information. Use of web position statements and social 
media positive ‘influencers’ from official health providers25 
may also be important tools to counter- balance fake infor-
mation from the strong paramedicine market.
A step in the right direction has been that the Amer-
ican Cancer Society (ACS), the National Cancer Insti-
tute (NCI), the European Society for Medical Oncology 
(ESMO) and the ECPC have recently provided some 
updated web recommendations for cancer- related pain 
and/or cachexia.26–30 Of note, ESMO also provides trans-
lation for patient guidelines in multiple languages.31 Form 
of guidance for patients with cancer and doctor- approved 
cancer information from the American Sociality of Clin-
ical Oncology (ASCO) had been also supplied in  cancer. 
net web site and in twitter by CancerDotNet.32 33
We believe and suggest (in respect of each national 
society/institution legitimate rights, sovereignty of deci-
sion and freedom of expression) each National oncology 
society (radiation, surgical, medical, nursing oncology) to 
produce web recommendations for patients either of their 
own or as a cyber e- link to available official guidelines and 
translated to each country’s national language(s). The 
ACS, ASCO, American Society for Radiation Oncology, 
ESMO, European Society for Radiotherapy and Oncology, 
European Society of Surgical Oncology, European School 
of Oncology, European Oncology Nursing Society, ECPC, 
National Comprehensive Cancer Network, NCI, Interna-
tional Society of Paediatric Oncology, European Society of 
Paediatric Oncology and all the other major international 
gatekeeper societies for oncology patients need to closely 
embrace and further develop this new field of internet 
education in order to protect patients against fake e- medi-
cine and the counterfeit drug and supplement web market.
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